Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Matthew Wojdyla"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommen
Externí odkaz:
https://doaj.org/article/2a2de03e79f148b6ad3b812d310abfe8
Autor:
Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV d
Externí odkaz:
https://doaj.org/article/6b66e6d3a8c14c57a799f9529b689f38
Autor:
Hanny Al‐Samkari, Debbie Jiang, Terry Gernsheimer, Howard Liebman, Susie Lee, Matthew Wojdyla, Michael Vredenburg, Adam Cuker
Publikováno v:
British Journal of Haematology. 197:359-366
Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO-RA) but not another. Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b13ed4f35fe4d9e16e5adfd3f27ddeb
https://doi.org/10.1111/bjh.18081
https://doi.org/10.1111/bjh.18081
Autor:
Tara Gonzales, Aurore Bergamasco, Tiffany Cristarella, Camille Goyer, Matthew Wojdyla, Abiola Oladapo, John Sawicky, John Yee, Yola Moride
Publikováno v:
American Journal of Perinatology.
Objective Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::127c7b8a281daf52b57c5a3ec1f0df3c
https://doi.org/10.1055/a-1990-2633
https://doi.org/10.1055/a-1990-2633
Autor:
Hanny Al-Samkari, Debbie Jiang, Terry Gernsheimer, Howard Liebman, Susie Lee, Chelsea Bernheisel, Matthew Wojdyla, Michael Vredenburg, Adam Cuker
Publikováno v:
Research and Practice in Thrombosis and Haemostasis. 7:100134
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42b544c8acee0649805eda9af1367bee
https://doi.org/10.1016/j.rpth.2023.100134
https://doi.org/10.1016/j.rpth.2023.100134
Autor:
Debbie Jiang, Adam Cuker, Howard A. Liebman, Hanny Al-Samkari, Matthew Wojdyla, Chelsea Bernheisel, Terry B. Gernsheimer, Scott Kolodny, Michael Vredenburg, Brian Jamieson, Susie Lee
Publikováno v:
Blood. 138:1015-1015
BACKGROUND : Thrombopoietin receptor agonists (TPO-RAs) are widely utilized second-line treatments for immune thrombocytopenia (ITP). The TPO-RAs eltrombopag and romiplostim have been FDA approved for over a decade with established efficacy and safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4dd0ade4eeaf09214d1d2741e7bb449
https://doi.org/10.1182/blood-2021-151321
https://doi.org/10.1182/blood-2021-151321
Publikováno v:
Blood. 136:22-23
Background: The clinical management of ITP has been evolving. Thrombopoietin receptor agonists (TPO-RAs) have become widely utilized as subsequent treatments, and the 2019 ASH guidelines recommend their use over rituximab to achieve a durable respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1035ba99252484e050fc5002e76795c0
https://doi.org/10.1182/blood-2020-142764
https://doi.org/10.1182/blood-2020-142764